FTT PET/CT Imaging for Breast Cancer

Recruiting in Palo Alto (17 mi)

Overseen byElizabeth McDonald, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Abramson Cancer Center at Penn Medicine

Stay on Your Current Meds

No Placebo Group

Trial Summary

What is the purpose of this trial?Up to 30 evaluable participants with known or suspected breast cancer (BIRADS 5 by imaging) will undergo FTT PET/CT imaging before primary surgery or neoadjuvant therapy. Patients undergoing neoadjuvant therapy may choose to have a second FTT PET/CT scan after the start of therapy (1 days to 3 weeks). FTT PET/CT uptake will be correlated with pathology measures and treatment response, in subjects undergoing neoadjuvant therapy

Eligibility Criteria

This trial is for adults over 18 with suspected or confirmed breast cancer, showing a lesion of at least 1 cm on imaging. Participants must be willing to provide tissue samples and consent to research use. It's not suitable for those who can't tolerate imaging procedures, have conditions compromising safety/participation, or are pregnant/breastfeeding.

Inclusion Criteria

I am diagnosed or highly suspected to have primary breast cancer.

I have a breast lesion that is at least 1 cm large, confirmed by imaging.

I am 18 years old or older.

+2 more

Exclusion Criteria

My doctor thinks I have a health issue that could make joining the study unsafe for me.

Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.

You cannot handle medical imaging procedures, according to your doctor's opinion.

Participant Groups

[18F]FluorThanatrace (FTT) PET/CT scans are being tested in up to 30 participants before surgery or therapy for breast cancer. The study may include a second scan after starting therapy to correlate FTT uptake with pathology and treatment response.

1Treatment groups

Experimental Treatment

Group I: Single ArmExperimental Treatment1 Intervention